Domperidone Dosing and Safety for Gastroparesis

Standard Dosing Regimen

• The American Gastroenterological Association recommends starting with 10 mg TID or QID as the initial therapeutic dose for gastroparesis symptoms 1

Important Context and Positioning

• The American College of Gastroenterology notes that domperidone is NOT FDA-approved in the United States but is available in Canada, Mexico, and Europe 2, 3, 4
• The American Heart Association recommends that doses above 10 mg TID are not recommended due to QT prolongation risk 1

Treatment Hierarchy

• The American Diabetes Association suggests that domperidone should be considered as an alternative prokinetic agent when metoclopramide is contraindicated or not tolerated 2, 3

Safety Profile and Monitoring

• The American College of Cardiology recommends obtaining baseline ECG to assess QTc interval before initiating therapy and correcting electrolyte abnormalities before starting treatment 5
• The National Institute of Diabetes and Digestive and Kidney Diseases notes that domperidone has significantly fewer CNS side effects compared to metoclopramide 2, 3

Common Pitfalls to Avoid

• The FDA recommends not exceeding 10 mg TID in the U.S. due to increased QT prolongation risk at higher doses 1
• The American Gastroenterological Association advises not to prescribe without baseline ECG and electrolyte assessment 5
• The National Institute of Neurological Disorders and Stroke suggests not using domperidone in patients with Parkinson's disease due to dopamine antagonism 5